Altimmune, Inc. (ALT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Altimmune, Inc. (ALT) Healthcare & Pipeline Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company specializing in developing novel peptide-based therapeutics for obesity and liver diseases. Their lead candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, is undergoing Phase 1b trials, positioning Altimmune within the competitive metabolic disease treatment landscape.

What Is the Investment Thesis for ALT?

Altimmune's investment thesis centers on the potential of pemvidutide, its lead drug candidate, to capture a significant share of the rapidly expanding obesity and NASH treatment markets. Pemvidutide's dual-agonist mechanism offers a differentiated approach compared to existing GLP-1 receptor agonists. Successful Phase 1b trial results could serve as a major catalyst, driving investor confidence and potentially leading to strategic partnerships. The company's HepTcell program, while earlier in development, represents a longer-term value driver in the HBV treatment space. Key risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. The company's current market capitalization of $574M reflects both the potential and the inherent risks associated with clinical-stage biopharmaceutical companies.

Based on FMP financials and quantitative analysis

ALT Key Highlights

Pemvidutide, Altimmune's lead product candidate, is currently in Phase 1b clinical trials for obesity and NASH, targeting large and growing markets.

• HepTcell, an immunotherapeutic for chronic HBV infection, is in Phase 2 clinical trials, representing a potential long-term value driver.
• Altimmune's GLP-1/glucagon dual receptor agonist approach with pemvidutide offers a differentiated mechanism compared to existing GLP-1 receptor agonists.
• The company's market capitalization is $0.31 billion as of May 9, 2026, reflecting the inherent risks and potential rewards of a clinical-stage biopharmaceutical company.
• Altimmune has a relatively small team of 59 employees, indicating a lean operational structure.

Who Are ALT's Competitors?

ALT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALT's Key Strengths?

Novel dual GLP-1/glucagon receptor agonist mechanism.

• Promising Phase 1b clinical trial data for pemvidutide.
• Experienced management team.
• Strong intellectual property portfolio.

What Are ALT's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources.
• High reliance on the success of pemvidutide.
• Small team size.

What Could Drive ALT Stock Higher?

Announcement of Phase 1b clinical trial results for pemvidutide in obesity (expected Q4 2026).

• Initiation of Phase 2 clinical trial for pemvidutide in NASH (expected Q1 2027).
• Enrollment and data readout from the Phase 2 clinical trial of HepTcell for chronic HBV.
• Potential for strategic partnerships with larger pharmaceutical companies.

What Are the Key Risks for ALT?

Negative return on equity (-42.6%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of pemvidutide to demonstrate efficacy or safety in clinical trials.
• Regulatory delays or rejection of Altimmune's drug candidates.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support clinical development.
• Patent challenges to Altimmune's intellectual property.

What Are the Growth Opportunities for ALT?

• Pemvidutide for Obesity: The global obesity market is projected to reach $45.1 billion by 2030. Altimmune's pemvidutide, with its dual GLP-1/glucagon receptor agonist mechanism, has the potential to capture a significant share of this market if it demonstrates superior efficacy and safety compared to existing treatments. The ongoing Phase 1b trial results will be crucial in determining the future trajectory of this program. Success in later-stage clinical trials could lead to regulatory approval and commercialization within the next 3-5 years.
• Pemvidutide for NASH: The NASH market is estimated to reach $25 billion by 2030. Pemvidutide's potential to address both weight loss and liver inflammation makes it a promising candidate for NASH treatment. Positive data from the Phase 1b trial could position pemvidutide as a leading contender in this market. Regulatory approval and commercialization could be achieved within the next 4-6 years, pending successful clinical trial outcomes.
• HepTcell for Chronic HBV: The market for chronic HBV treatment is substantial, with a significant unmet need for functional cures. HepTcell's immunotherapeutic approach offers a potential long-term solution for patients with chronic HBV infection. Positive results from the Phase 2 clinical trial could attract strategic partnerships and accelerate the development of this program. Commercialization could be possible within the next 5-7 years, contingent on successful clinical trial results and regulatory approval.
• Strategic Partnerships: Altimmune could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. Potential partners could be interested in pemvidutide for obesity and NASH, or HepTcell for chronic HBV.
• Expansion of Pipeline: Altimmune could expand its pipeline by developing new drug candidates targeting other metabolic and liver diseases. This could involve leveraging its expertise in peptide-based therapeutics and exploring new targets and mechanisms of action. A diversified pipeline would reduce the company's reliance on its lead product candidates and enhance its long-term growth potential.

What Are ALT's Competitive Advantages?

• Proprietary peptide-based therapeutic platform.
• Strong intellectual property protection for its drug candidates.
• Clinical trial data demonstrating the safety and efficacy of its therapies.
• Experienced management team with expertise in drug development and commercialization.

What Does ALT Do?

Altimmune, Inc., founded in 1997 and headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for obesity and liver diseases. Originally named Vaxin Inc., the company rebranded as Altimmune, Inc. in September 2015 to reflect its evolving focus. Altimmune's primary focus is on advancing novel peptide-based therapeutics. Their lead product candidate, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist currently in Phase 1b clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide aims to address the growing global health crisis of obesity and related metabolic disorders. In addition to pemvidutide, Altimmune is also developing HepTcell, an immunotherapeutic product candidate in Phase 2 clinical trials for patients chronically infected with the hepatitis B virus (HBV). HepTcell seeks to provide a functional cure for chronic HBV infection. Altimmune operates with a team of 59 employees, focusing on research, development, and clinical trials to bring innovative therapies to market.

What Products and Services Does ALT Offer?

• Develops peptide-based therapeutics for obesity and liver diseases.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Focuses on GLP-1/glucagon dual receptor agonists for metabolic disorders.
• Develops immunotherapeutic approaches for chronic viral infections.
• Seeks regulatory approval for its drug candidates from the FDA and other regulatory agencies.
• Aims to commercialize its therapies through strategic partnerships or independent sales efforts.

How Does ALT Make Money?

• Develops and patents novel drug candidates.
• Outlicenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties from partnered programs.
• Funds research and development through venture capital and public offerings.

What Industry Does ALT Operate In?

Altimmune operates within the biotechnology sector, specifically targeting the obesity and liver disease markets. The obesity market is experiencing significant growth, driven by increasing prevalence rates globally. The NASH market is also expanding rapidly, with limited approved therapies and a high unmet need. Competition in these markets is intense, with established pharmaceutical companies and other biotech firms vying for market share. Altimmune's success depends on demonstrating the safety and efficacy of its drug candidates in clinical trials and navigating the regulatory approval process.

Who Are ALT's Key Customers?

• Patients with obesity and related metabolic disorders.
• Patients with non-alcoholic steatohepatitis (NASH).
• Patients chronically infected with the hepatitis B virus (HBV).
• Pharmaceutical companies seeking to expand their portfolios of metabolic and liver disease treatments.

Altimmune, Inc. Financial Trajectory

Altimmune, Inc. (ALT) reported $26K in revenue for Q4 2025, reflecting 420.0% growth compared to the prior quarter. The company recorded a net loss of $27.4M, with diluted EPS of $-0.27.

Company Profile

Altimmune, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO Jerome Benedict Durso. ALT has traded publicly since 2017.

How Altimmune, Inc. Is Valued

Altimmune, Inc. carries a market capitalization of $574M, placing it in the small-cap category. Relative to its peer group, ALT's quantitative score of 23/100 is below the peer average of 74/100.

Return on equity for Altimmune, Inc. stands at -42.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 29.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.0%, the inverse of the P/E and a quick read on earnings relative to price.

Altimmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.85 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project Altimmune, Inc. revenue of about $2K for fiscal 2026, with EPS near $-0.60. The estimate reflects 6 contributing analysts.

Over the past six months, Altimmune, Inc. insiders filed 20 SEC Form 4 transactions — 0 sales and 20 purchases. On net that is roughly 1.2M shares acquired (about $3.5M) — insiders putting money in tends to read as conviction.

ALT Financials

ALT Latest News

ALT Analyst Consensus

ALT MoonshotScore

Altimmune, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources